IBRX - Conference and earnings call announcements

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio's recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio's EAP for rBCG to address U.S. shortages and provide an alternative source of BCG, a critical standard-of-care in bladder cancer Multiple urology centers across the U.S. are in the process of activating their sites to administer rBCG ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio's Expanded Access Program (EAP) for re

Immunotherapy innovator ImmunityBio, Inc. ((IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton London. Details of the presentation can be found below. Jefferies London Healthcare Conference Date: Tuesday, November 19, 2024 Time: 2:30 PM GT Format: Fireside chat with ImmunityBio company executives A replay of the recorded fireside presentation will be available through the Events and Presentations section of the ImmunityBio website at https://ir.immunitybio.com/ for 90 days. About ImmunityBio ImmunityBio is a vertically-integrated biotechno

The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio's Nant Cancer Vaccine (NCV) comprising a tri-valent Adenovirus (Tri-Ad5) in combination with the company's IL-15 superagonist N-803 could potentially prevent colon and other cancers in individuals with Lynch syndrome. With enrollment of the first two open-label phases of the trial completed, the study will now proceed to the randomized controlled phase. When fully enrolled, the completed randomized Phase 2 study will include up to 186 individuals. In the randomized controlled phase 138 participants will be randomized to ImmunityBio's NCV or placebo. Lynch syndrome is a

ImmunityBio, Inc. ((IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 35th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 28-30, 2023. Details of the presentation can be found below. Piper Sandler Healthcare Conference Date     Thursday, November 30, 2023 Time:     10:30 am EST Format:     Fireside chat with Director and Senior Research Analyst Joseph Catanzaro, Ph.D. Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1644522&tp_key=54f83a05b0 A replay of the presentation will be available by visiting the "Events" sect

ImmunityBio, Inc. ((IBRX), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023, at 10:00 am Eastern Time (ET) at the Marriott Marquis, New York. An audio webcast of the presentation will be accessible under the "Events & Presentations" section of the Company's investor relations website at ir.immunitybio.com. Management will be available during the conference for one-on-one meetings. About ImmunityBio ImmunityBio is a vertically-integrated, clinical-stage biotechnology com

ImmunityBio, Inc. ((IBRX), a clinical-stage immunotherapy company, announced today that the company will be participating in the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York City, November 29 - December 1, 2022. Details of the presentation can be found below. Piper Sandler Healthcare Conference Date: Tuesday, November 29, 2022 Time: 2:30 - 2:55 pm EST Format: Fireside chat with Director and Senior Research Analyst Joseph Catanzaro, Ph.D. Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1584249&tp_key=3f1d3e7b06 A replay of the presentation will be available by visiting the "Events" section of the Immu

ImmunityBio, Inc. ((IBRX), a clinical-stage immunotherapy company, announced today that the company will be presenting at the Jefferies London Healthcare Conference, which is taking place in London from November 15-17, 2022. Details of the presentation can be found below. Jefferies London Healthcare Conference Date: Tuesday, November 15, 2022 Time: 4:25–4:55 PM BST Format: Corporate Presentation and Q&A Session Webcast Link: https://wsw.com/webcast/jeff255/ibrx/1861731 A replay of the presentation will be available by visiting the "Events" section of the ImmunityBio website and will be archived for 90 days. About ImmunityBio ImmunityBio is a cli

ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will deliver a company presentation at the 2021 Jefferies London Healthcare Conference, which is being held November 16-18, 2021. Dr. Soon-Shiong will present updates on ImmunityBio's infectious disease and oncology programs. Management will be available during the conference for virtual one-on-one meetings. Presentation Details: Date: November 18, 2021 Format: The webcast will be available to all conference attendees, on-demand beginning on Thursday, November 18 at 8:00 am GMT/3:00 am EDT

ImmunityBio, Inc. ((IBRX), a clinical-stage immunotherapy company, today announced that Founder and Executive Chairman Dr. Patrick Soon-Shiong will deliver a company presentation at the 2021 Jefferies Virtual Healthcare Conference, which is being held June 1-4, 2021. Dr. Soon-Shiong will present updates on ImmunityBio's infectious disease and oncology programs. Management will be available during the conference for virtual one-on-one meetings. Presentation Details: Date: Friday, June 4 Time: 11:30 a.m. EDT Following the presentation, a live video webcast may be accessed through the Investor Relations section of the ImmunityBio website, www.ir.immunitybio.com. About ImmunityBio ImmunityB